EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bolt Biotherapeutics's Enterprise Value is $7.87 Mil.
Bolt Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-34.51 Mil. Therefore, Bolt Biotherapeutics's EV-to-FCF for today is -0.23.
The historical rank and industry rank for Bolt Biotherapeutics's EV-to-FCF or its related term are showing as below:
BOLT'
s EV-to-FCF Range Over the Past 10 Years
Min: -24.38 Med: 0.4 Max: 1.7
Current: -0.23
During the past 8 years, the highest EV-to-FCF of Bolt Biotherapeutics was 1.70. The lowest was -24.38. And the median was 0.40.
BOLT's EV-to-FCF is ranked worse than 100% of 336
companies
in the Biotechnology industry
Industry Median: 14.885
vs BOLT: -0.23
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bolt Biotherapeutics's PE Ratio (TTM) for today is calculated as:
Bolt Biotherapeutics's share price for today is $4.40.
Bolt Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bolt Biotherapeutics EV-to-FCF Related Terms
Bolt Biotherapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bolt Biotherapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bolt Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bolt Biotherapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bolt Biotherapeutics's EV-to-FCF falls into.
Bolt Biotherapeutics's current Enterprise Value is $7.87 Mil.
Bolt Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bolt Biotherapeutics (BOLT) has a EV-to-FCF of -0.23 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bolt Biotherapeutics and its competitors. According to the industry distribution chart, Bolt Biotherapeutics ranks #999999 out of 336 companies in the Biotechnology industry.
Is Bolt Biotherapeutics' EV-to-FCF too high?
Bolt Biotherapeutics' current EV-to-FCF is -0.23. Based on the distribution chart, Bolt Biotherapeutics ranks #999999 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bolt Biotherapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' EV-to-FCF compare to AIM and ERNA?
According to the Biotechnology industry distribution chart, Bolt Biotherapeutics ranks #999999 out of 336 companies for EV-to-FCF. This places Bolt Biotherapeutics in the lower half of its industry. The industry median EV-to-FCF is 14.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.89, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bolt Biotherapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bolt Biotherapeutics's current EV-to-FCF is -0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bolt Biotherapeutics (BOLT) is currently considered Possible Value Trap. The stock's GF Value™ is $9.03, compared to a current price of $4.40 — trading 51.3% below its estimated fair value. The current EV-to-FCF is -0.23. Bolt Biotherapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bolt Biotherapeutics (BOLT), the current EV-to-FCF is -0.23 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bolt Biotherapeutics (BOLT) Overvalued in 2026?
Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued.
The current stock price of $4.40 is trading 51.3% below its estimated GF Value™ of $9.03.
GuruFocus considers Bolt Biotherapeutics to be Possible Value Trap.
Key valuation signals for BOLT:
EV-to-FCF: -0.23
GF Value™: $9.03 vs. price of $4.40 (51.3% below fair value)
No single metric tells the full story. See the BOLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score
Get the complete analysis for BOLT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOLT has been successfully added to your 
